These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
458 related articles for article (PubMed ID: 24108069)
21. Late development of a lamellar macular hole after the spontaneous separation of vitreoretinal traction: case report. Rodríguez A; Rodríguez FJ; Valencia M; Castaño C Eur J Ophthalmol; 2016 Nov; 26(6):e168-e170. PubMed ID: 27445071 [TBL] [Abstract][Full Text] [Related]
22. Morphological Reconstitution and Persistent Changes After Intravitreal Ocriplasmin for Vitreomacular Traction and Macular Hole. Zandi S; Freiberg F; Vaclavik V; Pfister IB; Traine PG; Kaya C; Michels S; Garweg JG J Ocul Pharmacol Ther; 2020 Mar; 36(2):126-132. PubMed ID: 31934816 [No Abstract] [Full Text] [Related]
23. Oct-based interpretation of the vitreomacular interface and indications for pharmacologic vitreolysis. Stalmans P; Duker JS; Kaiser PK; Heier JS; Dugel PU; Gandorfer A; Sebag J; Haller JA Retina; 2013; 33(10):2003-11. PubMed ID: 23881226 [TBL] [Abstract][Full Text] [Related]
24. The epidemiology of vitreoretinal interface abnormalities as detected by spectral-domain optical coherence tomography: the beaver dam eye study. Meuer SM; Myers CE; Klein BE; Swift MK; Huang Y; Gangaputra S; Pak JW; Danis RP; Klein R Ophthalmology; 2015 Apr; 122(4):787-95. PubMed ID: 25556116 [TBL] [Abstract][Full Text] [Related]
28. Rate and timing of spontaneous resolution in a vitreomacular traction group: should the role of watchful waiting be re-evaluated as an alternative to ocriplasmin therapy? Dimopoulos S; Bartz-Schmidt KU; Gelisken F; Januschowski K; Ziemssen F Br J Ophthalmol; 2015 Mar; 99(3):350-3. PubMed ID: 25342274 [TBL] [Abstract][Full Text] [Related]
29. [Ocriplasmin as a treatment option for symptomatic vitreomacular traction with and without macular hole. First clinical experiences]. Maier M; Abraham S; Frank C; Feucht N; Lohmann CP Ophthalmologe; 2015 Dec; 112(12):990-4. PubMed ID: 26062717 [TBL] [Abstract][Full Text] [Related]
30. The International Vitreomacular Traction Study Group classification of vitreomacular adhesion, traction, and macular hole. Duker JS; Kaiser PK; Binder S; de Smet MD; Gaudric A; Reichel E; Sadda SR; Sebag J; Spaide RF; Stalmans P Ophthalmology; 2013 Dec; 120(12):2611-2619. PubMed ID: 24053995 [TBL] [Abstract][Full Text] [Related]
31. Intravitreal ocriplasmin: A breakthrough in the treatment of vitreomacular traction? Mec-Słomska AE; Adamiec-Mroczek J; Kuźmicz E; Misiuk-Hojło M Adv Clin Exp Med; 2017; 26(3):527-531. PubMed ID: 28791829 [TBL] [Abstract][Full Text] [Related]
32. Macular hole formation and spontaneous closure after vitrectomy for vitreomacular traction documented in spectral-domain optical coherence tomography. Odrobina D; Laudańska-Olszewska I; Gozdek P; Maroszyński M; Amon M BMC Ophthalmol; 2014 Feb; 14():17. PubMed ID: 24552161 [TBL] [Abstract][Full Text] [Related]
33. Results of the 2-Year Ocriplasmin for Treatment for Symptomatic Vitreomacular Adhesion Including Macular Hole (OASIS) Randomized Trial. Dugel PU; Tolentino M; Feiner L; Kozma P; Leroy A Ophthalmology; 2016 Oct; 123(10):2232-47. PubMed ID: 27499517 [TBL] [Abstract][Full Text] [Related]
39. From the analysis of pharmacologic vitreolysis to the comprehension of ocriplasmin safety. Morescalchi F; Gambicorti E; Duse S; Costagliola C; Semeraro F Expert Opin Drug Saf; 2016 Sep; 15(9):1267-78. PubMed ID: 27388220 [TBL] [Abstract][Full Text] [Related]